PIM1 and hematologic disorder: Thus, despite promising results of preclinical studies highlighting a potential therapeutic relevance of Pim kinases in hematologic malignancies, the clinical benefit is disappointing so far, which raises questions about potential mechanisms mitigating the effects of therapeutic Pim inhibition.